Dolomite Bio launches Nadia Go - An affordable microfluidic system for custom protocol development
The new system combines the microfluidic technology underlying their Nadia Instrument, with the customizable parameters of the Nadia Innovate
26 Sept 2022
A compact, affordable microfluidic system for custom microfluidic and genomics research was launched on September 21, 2022. This new system from Dolomite Bio combines the microfluidic technology underlying their Nadia Instrument, with the customizable parameters of the Nadia Innovate, granting access to the custom microfluidic protocol development without the necessity of large capital outlay.
Currently, most custom microfluidic research is performed using older complex modular systems. These are notoriously tricky and time-consuming to set up, unreliable, and require some level of expertise in microfluidics to be effective. In contrast, Nadia Go has a small footprint, no tubing, no PDMS, uses single-use chips, and has a semi-automated setup, with parameters controlled through easy-to-use PC software.
In addition to solving the drawbacks of modular systems, Nadia Go is a completely open platform, created with the ‘tinkerers’ in mind. Using Dolomite Bio’s core pressure-controlled microfluidics technology, Nadia Go enables the development of user-defined single-cell protocols and applications. Create, change, test, and save novel protocols and biological workflows through the adjustment of user-defined parameters such as droplet size, droplet frequency, temperature, agitation, and timing. Plus, observe droplet formation in real-time with the Nadia Go’s high-speed microscope and camera for easy process visualization. Giving researchers complete freedom from standard protocols and applications, as well as the liberty to create and share novel protocols with other users.
Mark Gilligan, the CEO of Dolomite Bio, spoke about the drive behind the Nadia Go launch "We’ve gone further to democratize science by developing the Nadia Go, a cost-effective system making microfluidics accessible to an even greater number of researchers".